吉非替尼治疗非小细胞肺癌的临床疗效

The analysis of clinical efficacy of Gefitinib in treatment of non-small cell lung cancer

目的:分析吉非替尼治疗非小细胞肺癌(NSCLC)的临床疗效及其安全性。方法:随机选取2012年9月至2014年8月入住我院接受治疗的112例非小细胞肺癌(NSCLC)患者作为研究对象,将患者随机分成观察组和对照组,每组56例,其中观察组给予吉非替尼治疗,对照组给予吉西他滨联合顺铂(GP方案)治疗,观察治疗疗效以及不良反应情况。结果:观察组患者治疗后有效率46.42%,控制率为80.36%,均显著高于对照组26.79%和57.14%;观察组患者腹泻和皮疹的发生率显著高于对照组,而贫血、血小板数减少、恶心以及呕吐的发生率明显低于对照组,差异均具有统计学意义(P<0.05)。结论:吉非替尼可有效治疗非小细胞肺癌,延缓肿瘤进程,提高患者生存质量,具有较好的临床应用价值。

Objective：To analyze the clinical effects and security of Gefitinib in treatment of non-small cell lung cancer.Method：From September 2012 to August 2014,112 patients in our hospital who accepted treatment were selected as the study samples.They were divided into two groups which included observation group（n=56）and control group（n=56）by random number table method.Observation group administered Gefitinib,however,control group were given gemcitabine plus cisplatin.The therapeutic efficacy and adverse reactions were recorded.Results：The effective rate was 46.42% and disease control rate was 80.36% in the observation group,significantly higer than the control group（26.79% and 57.14%）.Moreover,The incidence of exanthem and diarrhea in observation group were obviously higher than those in the control group.However,The incidence of vomiting,nausea,anemia and the fall of platelet count in control group were significantly lower than those in the control group,and the difference had statistical significance（P〈0.05）.Conclusion：Gefitinib can effectively treat non-small cell lung cancer,delay the development of cancer,and improve the quality of survial.Gefitinib has good clinical application value.